申请人:John Wyeth & Brother, Limited
公开号:US05369103A1
公开(公告)日:1994-11-29
##STR1## where A is an alkylene chain of 1 or 2 carbon atoms optionally substituted by one or more lower alkyl groups, R is hydrogen or lower alkyl, R.sup.1 is a mono or bicyclic aryl or a heteroaryl radical, R.sup.2 is an aryl radical, a heteroaryl radical, or an aryl-or heteroaryl-lower alkyl radical, R.sup.3 is hydrogen, lower alkyl or aryl and R.sup.4 is hydrogen, lower alkyl, cycloalkyl, cycloalkyl(lower)alkyl, aryl, or aryl(lower)alkyl or R.sup.3 and R.sup.4 together with the nitrogen atom to which they are both attached represent a saturated heterocyclic ring which may contain a further hetero atom and the dotted line represents a single or double bond, the hydrogen atoms shown in brackets being present when the dotted line represents a single bond and their pharmaceutically acceptable acid addition salts are 5-HT.sub.1A binding agents which may be used, for example, for the treatment of CNS disorders such as anxiety.
##STR1##其中A是1或2个碳原子的烷基链,可选地取代一个或多个低烷基基团,R是氢或低烷基,R.sup.1是单环或双环芳基或杂环芳基基团,R.sup.2是芳基基团、杂环芳基基团或芳基或杂环芳基低烷基基团,R.sup.3是氢、低烷基或芳基,R.sup.4是氢、低烷基、环烷基、环烷基(低)烷基、芳基或芳基(低)烷基,或R.sup.3和R.sup.4与它们都连接的氮原子一起表示一个饱和的杂环环,该环可能包含进一步的杂原子,虚线表示单键或双键,方括号中显示的氢原子在虚线表示单键时存在,它们的药学上可接受的酸盐是5-HT.sub.1A结合剂,例如可用于治疗焦虑等中枢神经系统疾病。